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Central nervous system (CNS) tuberculosis, particularly tuberculous meningitis (TBM), is the severest form of Mycobacterium
tuberculosis (M.Tb) infection, causing death or severe neurological defects in more than half of those aﬀected, in spite of recent
advancements in available anti-tuberculosis treatment. The deﬁnitive diagnosis of CNS tuberculosis depends upon the detection
of M.Tb bacilli in the cerebrospinal ﬂuid (CSF). At present, the diagnosis of CNS tuberculosis remains a complex issue because the
most widely used conventional “gold standard” based on bacteriological detection methods, such as direct smear and culture
identiﬁcation, cannot rapidly detect M.Tb in CSF specimens with suﬃcient sensitivity in the acute phase of TBM. Recently,
instead of the conventional “gold standard”, the various molecular-based methods including nucleic acid ampliﬁcation (NAA)
assay technique, particularly polymerase chain reaction (PCR) assay, has emerged as a promising new method for the diagnosis of
CNS tuberculosis because of its rapidity, sensitivity and speciﬁcity. In addition, the innovation of nested PCR assay technique is
worthy of note given its contribution to improve the diagnosis of CNS tuberculosis. In this review, an overview of recent progress
of the NAA methods, mainly highlighting the PCR assay technique, was presented.
1.Introduction
Central nervous system (CNS) disease caused by Mycobac-
terium tuberculosis (M.Tb), particularly tuberculous menin-
gitis (TBM), is uncommon and accounts for approximately
1% of all tuberculosis cases in the United States [1, 2]. CNS
tuberculosis is the severest form of M.Tb infection, causing
death or severe neurological defects in more than half of
those aﬀected, in spite of recent advancements in available
antituberculosis treatment (ATT) [1–5]. In addition, owing
to an increasing number of immunocompromised hosts
caused by the prevalence of AIDS, increasing numbers of
older people, the wider use of immunosuppressive agents,
and other factors, TBM remains a serious clinical and social
problem [1–5]. Owing to its relative rarity and the wide
spectrum of its neurological symptoms, CNS tuberculosis
remains a formidable diagnostic challenge [1–5]. In TBM,
accurate and rapid diagnosis and early treatment for tuber-
culosis are the most important factors with regard to the
prognosis and the prevention of long-term neurological
sequelae [1–5]. However, the conventional “gold standard”
based on bacteriological detection methods of M.Tb, includ-
ing the direct smear examination for acid-fast bacilli (AFB)
and culture identiﬁcation, is inadequate for early diagnosis,
owing to the poor sensitivity or the long time required (4–8
weeks) for cultures [1–5].
Recently,thedetectionofM.TbDNAinthecerebrospinal
ﬂuid (CSF) through the use of various molecular-based
methods, including nucleic acid ampliﬁcation (NAA) assay
technique, particularly polymerase chain reaction (PCR)
assay, has emerged as a promising new method for the
diagnosis of CNS tuberculosis because of its rapidity,
sensitivity, and speciﬁcity [2–42]. Many investigators have
reported on the usefulness of PCR assay for the detection
of M.Tb DNA in CSF, although the sensitivity of PCR
assay has signiﬁcant discrepancies (65–83%) between each
type of measuring methods and diﬀerent laboratories [2–
42]. Moreover, nested PCR assay has been reported as
a prominent method for detecting M.Tb DNA in CSF2 Tuberculosis Research and Treatment
[3, 4, 17, 19, 24–27, 32]. This new method drastically
increases the sensitivity and speciﬁcity of DNA ampliﬁcation
compared with conventional single-step PCR [3, 4, 17,
19, 24–27, 32]. However, the nested PCR assay using CSF
samples has yet to be widely used in TBM diagnosis owing to
its laborious and time-consuming procedure, which carries
a high risk of cross-contamination [3, 4, 17, 19, 24–27,
32]. Currently, real-time PCR assay is applied in routine
diagnostic laboratory testing [33, 38, 40–42]. In addition to
conventional qualitative analysis, real-time PCR assay makes
it possible to perform accurate quantitative analyses with a
high degree of reproducibility [33, 38, 40–42].
In this paper, the authors highlight the recent advance-
ment of NAA assay techniques, in particular PCR assay and
provide an overview of the current issues and evolution of
diagnosis and clinical aspects of CNS tuberculosis.
2. The Global Epidemiologic Burden
of Tuberculosis
In 2007, the World Health Organization (WHO) estimated
that 9.27 million new cases (139/100,000 population) of
active tuberculosis occur annually, resulting in an estimated
1.6 million deaths per year [1, 2]. Tuberculosis remains a
worldwide burden, with a large majority of new active tuber-
culosis cases occurring in underdeveloped and developing
countries [1, 2]. In fact, India, China, Indonesia, Nigeria,
and South Africa rank ﬁrst to ﬁfth in the total number
of incident cases of tuberculosis [1, 2]. In 80% of new
tuberculosis cases, social and demographic factors such as
poverty, overcrowding, malnutrition, and a compromised
immunesystemplayamajorroleintheworldwideepidemic,
while the remaining 20% of tuberculosis cases are associated
with HIV in sub-Saharan Africa [1, 2]. Among the 9.27
million new tuberculosis cases in 2007, an estimated 1.37
million (14.8%) were HIV positive [1, 2].
CNS infection is one of the severest forms of tuber-
culosis [1–5]. In a large-scale epidemiological study of
extrapulmonary tuberculosis in the United States, CNS
involvement was noted in 5 to 10% of extrapulmonary
tuberculosis cases, with more recent CDC data in 2010
indicating that 5.5% of extrapulmonary cases involve CNS
tuberculosis (=1.2% of total tuberculosis cases) [43–46].
In the largest prospective epidemiological study of CNS
tuberculosis, the incidence of developing CNS tuberculosis
was approximately 1.0% among 82,764 tuberculosis cases
from 1970 to 2001 in a Canadian cohort [1, 2, 43].
However, despite an overall decrease in the total number of
tuberculosis cases in advanced nations such as the United
States, a gradual and continuous increase in the proportion
of extrapulmonary tuberculosis cases has been reported [1,
2, 43–46]. This increase has been mainly attributed to the
recent increase of immunocompromised patients and the
HIV/AIDS epidemic [1, 2, 43–46]. In addition, although the
overall population-based mortality rate from tuberculosis is
lowanddecreasing,severalstudieshaveshownthatmortality
ratesaresubstantiallyhigherinpatientswithseveralformsof
extrapulmonary tuberculosis, including CNS tuberculosis or
TBM and disseminated disease [1, 2, 43–46].
Several risk factors for CNS tuberculosis have been
identiﬁed. Both age (children > adults) and HIV-coinfected
patients are at high risk for developing CNS tuberculosis
[1, 2, 44]. Other risk factors include malnutrition, recent
measles in children, alcoholism, malignancies, the use of
immunosuppressive agents in adults, and disease prevalence
in the community [1, 2]. Several studies in developed
countries have also identiﬁed that foreign-born individuals
(individuals born outside of developed countries) are over-
represented among CNS tuberculosis cases [1, 2, 44–46].
3. CurrentIssues for Diagnosis in
CNS Tuberculosis
At present, the diagnosis of CNS tuberculosis remains a
complex issue because the most widely used conventional
bacteriological detection methods, such as direct smear for
AFB and culture for M.Tb, cannot rapidly detect M.Tb
in CSF specimens with suﬃcient sensitivity in the acute
phase of TBM [2–42]. Rapid and accurate diagnosis in the
acute phase of CNS tuberculosis and early starting ATT are
the most important factors with regard to the prognosis
and the prevention of long-term neurological sequelae [2–
5]. The poor sensitivity and often delayed results from
the conventional “gold standard” based on microbiological
techniques in the traditional TBM diagnosis underscore the
need for a more sensitive, rapid, and accurate diagnostic
method in clinical practice [2–5]. Several molecular-based
methods, often drawn from successful techniques used for
the diagnosis of tuberculosis in respiratory specimens, have
been evaluated for their applicability in the diagnosis of
CNS tuberculosis. These techniques include commercially
available NAA methods and other PCR-based methods [2–
42]. In addition, the use of neuroradiographic techniques
such as magnetic resonance imaging (MRI) has prominently
improved the diagnostic accuracy of TBM and tubercu-
lomas [2, 47–49]. Recently, the role of neuroradiographic
techniques in the evaluation of CNS tuberculosis has
been reviewed in various reports [1–5, 47–49]. Commonly
identiﬁed neuroradiological features of TBM include basal
meningeal enhancement, hydrocephalus, and infarctions in
the supratentorial brain parenchyma and brain stem [2, 47–
49]. Moreover, tuberculomas are generally deﬁned as low-
or high-intensity, round or lobulated masses with irregular
walls and show homogeneous or ring enhancement after
the administration of contrast [2, 47–49]. They occur as
solitary or multiple nodules and are typically found in
the frontal and parietal lobes [2, 47–49]. However, the
diﬀerential diagnosis of tuberculomas and other intracranial
focal massive lesions such as fungal granulomas is diﬃcult
when using only neuroradiographic techniques [2]. There-
fore, the combination of molecular-based techniques and
neuroradiographictechniquesisregardedasapromisingand
powerful diagnostic tool for TBM and tuberculomas, instead
of neuroradiographic techniques with or without classical
bacteriological detection methods [2].Tuberculosis Research and Treatment 3
4.RecentAdvancementofPCRAssayTechnique
The NAA methods for M.Tb are diagnostic techniques to
demonstrate the presence of tubercle bacilli by the extraction
and ampliﬁcation of DNA or RNA of M.Tb from clinical
specimens such as sputum or CSF. The representative
DNA ampliﬁcation method is the PCR assay technique. In
this section, an overview of the principles of PCR assay
techniques is presented, mainly with regard to their recent
advancement and evolution.
4.1. The Basic Principle of PCR Assay. A schema indicating
the basic principle of the PCR assay is shown in Figure 1(a).
Fundamentally, the PCR assay technique depends on “ther-
mal cycling,” consisting of cycles with repeated heating
and cooling for the reactions of DNA denaturation and
enzymatic replication of DNA. Short DNA fragments called
“primers” containing sequences complementary to the target
region along with a DNA polymerase are key components
to enable sequence-speciﬁc DNA ampliﬁcation. The thermal
cycling procedure involves a ﬁrst step for physical separa-
tion of the two strands of DNA double helix at a high
temperature (94–98◦C for 20–30 seconds); this is called the
DNA denaturation step. At a lower temperature (50–65◦C
for 20–40 seconds), the primers that are complementary
to the target DNA region anneal to each separated single-
stranded DNA as the template; this is called the annealing
step. The speciﬁcity of PCR mainly results from both the
primer sequence setting that closely matches the template
sequence and the annealing temperature setting depending
on the length of primers. The DNA polymerase binds to
the primer-template hybrid and begins DNA synthesis. The
DNA polymerase enzymatically assembles and synthesizes a
new DNA strand complementary to the DNA template in
the 5  to 3  direction; this is called the extension/elongation
step. In general, almost all PCR applications employ a heat-
stable DNA polymerase, such as Taq polymerase, an enzyme
originally isolated from the bacterium Thermus aquaticus.A s
a result, it is possible to repeat serially the thermal cycling
procedure, consisting of alternate heating and cooling steps.
As the thermal cycling procedure progresses, the synthesized
DNA fragment is itself used as a template for replication,
setting in motion a “chain reaction” in which the DNA
template is exponentially ampliﬁed.
Through the use of agarose gel electrophoresis, the am-
pliﬁed DNA fragments can be separated by their lengths
(molecular weights). The agarose gel is then treated with
a solution containing ethidium bromide (EtBr), which is
the most commonly used dye for visualizing DNA bands in
agarose gel electrophoresis. Because EtBr ﬂuoresces under
UV light when intercalated into the major groove of DNA,
through EtBr treatment, the ampliﬁed target DNA fragment
can be visualized and detected as a distinctive band.
4.2. The Principle of Nested PCR Assay. A schema indicating
the principle of nested PCR assay is shown in Figure 1(b).
Nested PCR assay is a modiﬁed version of the PCR
technique intended to increase the ampliﬁcation eﬃciency
markedly and to reduce the level of nonspeciﬁc PCR
products due to the ampliﬁcation of untargeted primer
binding sites. Although the speciﬁcity of the standard single-
step PCR depends on the primers  complementarity to the
target DNA sequence,a commonly occurring problemis that
primers bind to other similar regions of the DNA, giving
untargeted PCR products such as primer dimers, hairpins,
and alternative primer target sequences. Nested PCR assay
requires two sets of primer pairs, used in two successive steps
of the PCR procedure. In particular, a second set of primer
pairs is prepared to amplify a secondary target within the
ﬁrst-stepPCRproduct;thisisthesourceoftheterm“nested”.
The ﬁrst set of primers ampliﬁes a fragment similarly to
the standard single-step PCR. However, the second set of
primers binds inside the ﬁrst-step PCR product to allow
ampliﬁcation of the second-step PCR product, which is
shorter than the ﬁrst one. The advantage of the nested PCR
assay is that, if an untargeted or nonspeciﬁc PCR product is
ampliﬁed,theprobabilityisquitesmallthattheregionwould
be ampliﬁed in the second-step PCR by the second set of
primers. Thus, nested PCR assay is an excellent technique
for obtaining a suﬃc i e n ta m o u n to ft a r g e tD N At h r o u g h
a two-step ampliﬁcation procedure, and for prominently
improving the speciﬁcity to the target sequence by reducing
the ampliﬁcation of nonspeciﬁc products.
4.3. The Principle of Real-Time Quantitative PCR Assay.
Real-time PCR assay is a variation of the PCR technique
intended to amplify and simultaneously quantify a targeted
DNA molecule; it enables both detection and quantiﬁcation.
Although the basic procedure of real-time PCR follows the
general principle of classical PCR, its key feature is that
the ampliﬁed DNA fragment is detected as the reaction
progresses in “real time.” This is a novel and revolutionary
approach compared with conventional standard PCR, where
the PCR product is detected at the end of the reaction
procedure. Two common methods for detection of products
in real-time PCR are as follows: (1) nonspeciﬁc ﬂuorescent
dyes such as SYBR Green that intercalate with any double-
stranded DNA and (2) sequence-speciﬁc oligonucleotide
probes such as TaqMan probe that are labeled with a
ﬂuorescent reporter dye, which permits detection only
after hybridization of the probe with its complementary
target sequence. The former (SYBR Green) will bind to all
double-stranded DNA PCR products including nonspeciﬁc
PCR products (such as primer dimer). This is a potential
disadvantage as it could obstruct accurate quantiﬁcation of
the intended target DNA fragment.
In contrast, ﬂuorescent reporter probes such as TaqMan
probe detect only the DNA fragment containing the com-
plementary probe sequence; therefore, use of such reporter
probes signiﬁcantly increases the speciﬁcity and enables
accurate quantiﬁcation, even in the presence of nonspeciﬁc
ampliﬁed fragments. A schema indicating the principle of
real-time quantitative PCR assay based on a ﬂuorescent
reporter probe (TaqMan PCR) is shown in Figure 1(c).
The sequence-speciﬁc oligonucleotide probe is labeled with
a ﬂuorescent reporter dye, such as FAM or VIC, at the 5 -4 Tuberculosis Research and Treatment
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Figure 1: Schemata of the principles of polymerase chain reaction (PCR) assay techniques. (a) A schema indicating the basic principle of
PCR assay. (b) A schema indicating the principle of nested PCR assay. (c) A schema indicating the principle of real-time (TapMan) PCR
assay.
end and conjugated with a quencher dye, such as TAMRA, at
the3 end.Thecloseproximitybetweenaﬂuorescentreporter
dye and a quencher dye prevents emission of its ﬂuorescence.
As the reaction is initiated, both probe and primers anneal
to the target DNA sequence during the annealing step of
PCR. As the PCR procedure progresses, breakdown of the
probe by the 5  to 3  exonuclease activity of Taq polymerase
separates the reporter from the quencher and thus allows
unquenched emission of ﬂuorescence of the reporter dye,
which can be detected after excitation with a laser. The
strength of ﬂuorescence increases exponentially because
ﬂuorescent reporter dyes separate from quencher dyes in a
manner corresponding to the progress of PCR cycles, and its
geometric increase is used to determine the threshold cycle
(Ct) value in order to calculate the ampliﬁcation rate in each
reaction. As a result, the primary amount of DNA can be
quantiﬁed accurately.
5.Commercially Available NAA
Methods for M.Tb
Currently, two commercially available NAA methods for the
direct detection of M.Tb complex have been approved by
the United States Food and Drug Administration (FDA),
as follows: Roche Amplicor Mycobacterium tuberculosis Test
(Roche Diagnostic Systems, Inc., Indianapolis, IN, USA) and
Gene-Probe Ampliﬁed Mycobacterium tuberculosis Direct
(MTD) Test (Gene-Probe, Inc., San Diego, CA, USA) [2, 6–
12]. Both tests use the 16S ribosomal (r) RNA gene of M.Tb
(GenBank accession no. NC 000962.2 (1471846–1473382))
as the target sequence for ampliﬁcation [2, 6–12]. The 16S
rRNA gene represents a stable property of microorganisms
and is widely used as the target for identifying mycobacterial
species [2, 6–12].
Roche Amplicor Test involves the conventional standard
PCR-based method. In this test kit, the DNA fragment
is ampliﬁed and detected by the primer pair and probe
that are speciﬁc for the 16S rRNA gene of M.Tb [2, 6, 8,
10]. In addition, Roche Cobas TaqMan MTB Test is the
improved successor to the Amplicor Test and adopts a real-
time(TaqMan)PCRassaytechnique.Meanwhile,Gen-Probe
MTD Test is the isothermal ampliﬁcation method for RNA
[2, 7, 9–12]. In this test kit, the 16S rRNA of M.Tb is
directly ampliﬁed by the coupling of reverse transcriptase
and RNA polymerase under a constant temperature (43◦C),
and detected by hybridization using speciﬁc oligo-RNATuberculosis Research and Treatment 5
probe [2, 7, 9–12]. At present, Amplicor is approved by the
FDA for testing of AFB smear-positive respiratory specimens
only [2, 6–12]. Meanwhile, MTD is approved for testing
of respiratory specimens, regardless of the result of smear
for AFB [2, 6–12]. Several studies have reported excellent
resultsforbothtests(sensitivityandspeciﬁcitylevelsofmore
than 95%) in AFB smear-positive respiratory specimens,
but reduced sensitivity (60 to 85%) when applied for AFB
smear-negative respiratory specimens [2, 6–12]. Neither test
is approved by the FDA for testing of CSF specimens [2, 6–
12].
6. Clinical Application of PCR Assay Technique
for the Diagnosis of CNS Tuberculosis
Table 1 summarizestheperformanceofPCR-basedassaysfor
the diagnosis of CNS tuberculosis [2, 6–42]. The challenges
of applying NAA assay techniques to the rapid diagnosis
of M.Tb in the CSF specimens stem largely from the small
number of bacilli typically present in TBM and the presence
of ampliﬁcation inhibitors in the CSF [2–42]. In actual
clinical practice, the sensitivity and speciﬁcity of PCR-based
assay methods are the most serious issues in the diagnosis of
CNS tuberculosis. In order to improve both the sensitivity
and the speciﬁcity of PCR assay, the eﬃcient extraction and
puriﬁcation of DNA from a small number of M.Tb bacilli
in the CSF specimens and the setting of primers to amplify
M.Tb DNA as the template speciﬁcally and eﬃciently are the
most important factors [2–42]. Therefore, many researchers
have worked intensively on these issues [2–42]. In the 1990s,
a number of improved extraction and puriﬁcation methods
ofM.TbDNAfromCSFspecimenswerereportedbyShankar
et al. [14], Kaneko et al. [13], and Lin et al. [20], According
to these studies, the CSF specimen was treated with cytolysis
buﬀer containing proteinase-K and sodium dodecyl sulfate
(SDS) as a surface-active agent, and then M.Tb DNA
was extracted and puriﬁed using phenol-chloroform and
ethanol precipitation from the treated CSF specimen [13,
14, 20] .I no r d e rt oe x t r a c tas m a l la m o u n to fM.Tb DNA
from a CSF specimen more eﬃciently, the authors used a
high-molecular-weightcarrier,Ethachinmate(NipponGene,
Tokyo, Japan), as a coprecipitating agent for the nucleotides
together with the previously reported phenol-chloroform
extraction and ethanol precipitation [3, 4, 32, 33, 38, 40,
41]. However, in recent studies, the conventional phenol-
chloroform extraction and ethanol precipitation have tended
to be regarded as inadequate for routine use in clinical exam-
inationsbecauseoftheirlaboriousandtime-consumingpro-
cedures [25–31, 34–37]. Generally, commercially available
column extraction kits, such as the QIAmp Blood Kit and
QIAmp DNA Mini Kit (Qiagen Inc., Valencia, CA, USA),
and the Cobas Amplicor respiratory specimen preparation
kit (Roche Diagnostic Systems, Inc., Indianapolis, IN, USA),
have been widely used for DNA extraction from various
s a m p l e si np r e v i o u ss t u d i e s[ 6–12, 25–31, 34–37]. However,
in the current study, it was impossible to extract M.Tb
DNA from CSF specimens suﬃciently using commercial
column extraction kits; therefore, these popular kits may be
inadequateforextractingasmallamountofM.TbDNAfrom
CSF specimens [3, 4, 32, 33, 38, 40, 41].
Currently, the four major M.Tb DNA-speciﬁc sequences,
including the regions of IS6110 insertion sequence (Rv3475:
GenBank accession no. NC 000962.2 (3891051–3892091)),
65-kDa heat shock protein antigen (Rv0251c: NC 000962.2
(302173–302652)), 16S rRNA gene and MPT64 (NC
000962.2 (2223343–2224029)) are evaluated by NAA assays
(Table 1)[ 6–42]. Of these four sequence regions, the IS6110
insertion sequence, which is a repetitive element exclusively
foundinthegenomeofM.Tbcomplex,hasbeenmostwidely
used as the target sequence with superior ampliﬁcation
eﬃciency in many studies (Table 1)[ 15, 16, 18, 19, 21,
22, 24, 25, 28, 34, 36, 37, 39]. In these previous studies,
PCR assays targeting the IS6110 insertion sequence revealed
relatively good results (an overall sensitivity of 70–98% and
speciﬁcity of 80–100%) for TBM diagnosis (Table 1). In
addition, next to the IS6110 insertion sequence, the 16S
rRNA gene has been frequently used for NAA assays, and it
is the target sequence of two commercially available M.Tb
detection methods, namely, the Roche Amplicor Test and
the Gen-Probe MTD Test, which have been approved by
the FDA for testing of respiratory specimens, as described
above [2, 6–12]. At present, no commercially available NAA
assay methods have been approved for testing of CSF, but
several studies have evaluated their performance in TBM
cases (Table 1)[ 2, 6–12]. A recent meta-analysis concerning
the accuracy of commercially available NAA assay methods
for TBM diagnosis revealed an overall sensitivity of 56%
a n ds p e c i ﬁ c i t yo f9 8 %[ 10]. On the basis of these results,
the commercially available NAA assay methods are evaluated
as follows: they may play a role in conﬁrming TBM, but
because of low sensitivity, they are not ideal for ruling
out TBM [2, 10]. As the major reason for the insensitive
performance of these two commercially available NAA assay
methods for TBM diagnosis, it is considered that, since they
have been approved for testing of respiratory specimens
containing relatively large numbers of M.Tb bacilli, they
are inadequate for detecting a small amount of M.Tb DNA
from CSF specimens. Recently, in several studies, Gen-
Probe MTD Tests modiﬁed to improve the performance for
detecting M.Tb DNA in CSF specimens have been reported
[7, 9, 11, 12]. However, the use of these modiﬁed techniques
was limited to a single laboratory, and they have not been
widely used [7, 9, 11, 12]. Meanwhile, MPT64 is the gene
sequence encoding the MPB64 protein that is speciﬁc for
M.Tb complex and exists at only one site on the M.Tb
genome. Therefore MPT64 is regarded as the most speciﬁc
sequence for PCR assays and has been used as the target
sequence for PCR in many studies (Table 1)[ 3, 4, 13, 14, 16,
17, 20, 23, 26, 27, 32, 33, 38, 40, 41]. Lee et al. [16]c o m p a r e d
threesequenceregions(IS6110,65kDaantigen,andMPT64)
and reported that MPT64 was the most speciﬁc and sensitive
sequence for the ampliﬁcation of M.Tb DNA by PCR.
Beyond the commercially available NAA methods, the
application of PCR-based methods to amplify M.Tb DNA
has received a lot of attention clinically (Table 1)[ 13–42].
As described above, in order to improve the performance of6 Tuberculosis Research and Treatment
Table 1: Performance of PCR-based assays for the diagnosing TBM.
Author Reported
year Assay technique Specimens and cases %
Sensitivity
%
Speciﬁcity Reference
Commercially available
NAA assays
Bonington et al. 1998 Roche amplicor PCR 83 CSF/69 patients (40 TBM,
29 non-TBM): South Africa 60 100 [6]
Lang et al. 1998 Modiﬁed Gen-Probe MTD 84 CSF and children (24 TBM,
60 non-TBM): Dominica 83 100 [7]
Bonington et al. 2000 Roche Cobas Amplicor PCR 83 CSF/69 patients (40 TBM,
29 non-TBM): South Africa 17.5 100 [8]
Chedore and Jamieson 2002 Gen-Frobe MTD 311 CSF: Canada †93.8 †99.3 [9]
Pai et al. 2003 Review and Meta-Analysis 14 studies with commercial
NAA assays 56 98 [10]
Thwaites et al. 2004 Gen-Probe MTD 341 CSF/152 patients (73
TBM, 79 non TBM): Vietnam 38 99 [11]
Cloud et a1. 2004 Modiﬁed Gen-Probe MTD 27 CSF specimens spiked with
M. tuberculosis 17–100 100 [12]
Other PCR-based assays
Kaneko et al. 1990 MPT64 single PCR 26 CSF and patients (6 TBM,
20 non-TBM): Japan 83.3 100 [13]
Shanker et al. 1991 MFT64 single PCR 85 CSF and patients (34 TBM,
51 non-TBM): India 65 88 [14]
Donald et a1. 1993 IS6110 single PCR 43 CSF/20 TBM chidren:
South Africa 80 — [15]
Lee et al. 1994 IS6110/65kDa antigen/MFT64
Single FCR
27 CSF and patients (6 TBM,
21 non-TBM): Singapore 100/83/83 38/67/90 [16]
Liu et al. 1994 MFT64 nested PCR 100 CSF and patients (21
TBM, 79 non-TBM): Taiwan 90 100 [17]
Folgueira et al. 1994 IS6110 single PCR 25 AIDS patients (11 TBM, 14
non-TBM): Spain 82 100 [18]
Scarpellini et al. 1995 IS6110 nested PCR 68 CSF/36 AIDS patients (12
TBM, 24 non-TBM): Italy 100 100 [19]
Lin et al. 1995 MFT64 single PCR 47 CSF/45 patients (18 TBM,
27 non-TBM): Taiwan 70 100 [20]
Kox et al. 1995 IS6110 single PCR 42 patients (24 TBM, 18
non-TBM): The Netherlands 48 100 [21]
Nguyen, et a1. 1996 IS6110 single PCR 136 TBM patients: Vietnam 32 100 [22]
Seth et a1. 1996 MFT64 single PCR 89 CSF and patients (40 TBM,
49 non-TBM): India 85 94 [23]
Wei et al. 1999 IS6110/65kDa antigen/MTF40
multiplex nested PCR
11 CSF and patients (5 TBM,
6 non-TBM): China 60 66 [24]
Caws et al. 2000 IS6110 nested PCR 131 TBM patients: United
Kingdom
†75 †94 [25]
Martins et al. 2000 MFT64 nested FCR 73 specimens (30 PF, 26 PB,
17 CSF): Brazil
†70 †88 [26]
Brienza et al. 2001 MPT64 nested PCR 91 patients (41 TBM, 50
non-TBM): Brazil 53 100 [27]
Narayanan et al. 2001 IS6110/TRC4 single PCR 96 CSF and patients (67 TBM,
29 non-TBM): India 80.5/91 79/76 [28]
Desai et al. 2002 pKSIO single PCR 120 CSF and patients (105
TBM, 15 non-TBM): India 31 100 [29]
Raﬁ and Naghily 2003 Single PCR (target not
available)
36 CSF and patients (29 TBM,
6 non-TBM): Iran 86.2 100 [30]
Kulkarni et a1. 2005 38 kDa protein single PCR 60 CSF and patients (30 TBM,
30 non-TBM): India 90 100 [31]
Takahashi et al. 2005 MPT64 nested PCR 29 CSF and patients (9 TBM,
20 non-TBM): Japan 100 100 [32]
Takahashi and Nakayama 2006 MPT64 QNRT-PCR 29 CSF and patients (9 TBM,
20 non-TBM): Japan 100 100 [33]
Quan et a1. 2006 IS61 10 single PCR 74 CSF and patients (25 TBM,
49 non-TBM): China 75 93.7 [34]
Desai et al. 2006 Single PCR (target not
available)
57 CSF and patients (30 TBM,
27 non-TBM): India 66.7 100 [35]Tuberculosis Research and Treatment 7
Table 1: Continued.
Author Reported
year Assay technique Specimens and cases %
Sensitivity
%
Speciﬁcity Reference
Raﬁ et al. 2007 IS6110 single PCR, MPT64/
65kDa antigen nested PCR
176 CSF and patients (75
TBM, 101 non-TBM): India 98/91/51 100/91/92 [36]
Raﬁ and Naghilys 2007 IS6110 uniplex (single) PCR 945 CSF and patients (677
TBM, 268 non-TBM): India 76.4 89.2 [37]
Takahashi et al. 2007 MPT64 QNRT-PCR 63 CSF/28 patients (8 TBM,
20 non-TBM): Japan 55.8 100 [38]
Deshpande et a1. 2007 IS6110 Single PCR 80 CSF and patients (51 TBM,
29 non-TBM): India 91.4 75.9 [39]
Takahashi et al. 2008 MPT64 WR-QNRT-PCR 96 CSF/53 patients (24 TBM,
29 non-TBM): Japan 95.8 100 [40, 41]
Haldar et al. 2009 devR qRT-PCR 167 CSF and patients (81
TBM, 86 non-TBM): India 87.6 92 [42]
NAA: nucleic acid ampliﬁcation, CSF: cerebrospinal ﬂuid, PF: pleural ﬂuids, PB: pleural biopsies, QNRT-PCR: quantitative nested real-time PCR,WR-QNRT-
PCR: wide range quantitative nested real-time PCR, pRT-PCR: quantitative real-time PCR, †: results versus culture as gold standard.
the PCR-based assays for the diagnosis of CNS tuberculosis,
various ideas and modiﬁcations have already been tried [2,
6–42]. Recently, as a revolutionary assay technique that con-
veysdrasticallyincreasedsensitivityandspeciﬁcitycompared
with the conventional standard PCR assay, nested PCR assay
has been innovated for the diagnosis of CNS tuberculosis [3,
4, 17, 19, 24–27, 32]. Liu et al. [17] reported that nested PCR
assay targeting MPT64 was performed for CSF specimens
collected from 21 patients with clinically suspected TBM
and enabled diagnosis of TBM with a sensitivity of 90%
and a speciﬁcity of 100% within 24 hours. In addition,
they reported that the nested PCR assay had approximately
1000 times higher sensitivity than the conventional single-
step PCR assay [17]. The authors performed the nested
PCR assay targeting MPT64 for the CSF specimens collected
from 9 patients with clinically highly suspected TBM [32].
In our study, both the sensitivity and the speciﬁcity of
nested PCR assay were 100%, but the sensitivity of the
conventional single-step PCR assay and culture for M.Tb
was only 22.2% [32]. Moreover, the minimum detection
sensitivity of our nested PCR assay technique was examined.
This technique enabled detection at a level as low as 1–10
copies/2µLo fp u r i ﬁ e dM.Tb DNA and had 1000 to 10,000
times higher sensitivity than the conventional single-step
PCR assay [32]. Concerning the relationship between the
PCR assay results and the responses for ATT, Lin et al.
[20] examined this relationship by conventional single-step
PCR assay and Scarpellini et al. [19] examined it by nested
PCR assay. In particular, Scarpellini et al. [19]p e r f o r m e d
diachronic study by nested PCR assay targeting IS6110 for
serial CSF specimens collected from 7 TBM patients during
the clinical treatment course. In their diachronic study,
the nested PCR assay results were converted from positive
to negative in 4 TBM patients whose clinical conditions
recovered during ATT [19].Incontrast,thenestedPCRassay
results remained positive throughout the clinical course in 3
patients who demonstrated no ATT response and died [19].
Therefore, Scarpellini et al. concluded that the nested PCR
assay was useful for assessing the clinical treatment course of
TBM [19]. Similarly, in our study, 11 out of 27 serial CSF
specimens that were available from the 7 patients with highly
suspected TBM and collected during the clinical treatment
course of ATT revealed positive results (40.7%) of the nested
PCR assay targeting MPT64 [32]. Moreover, our nested PCR
assayresultswereconvertedfrompositivetonegativeinthe6
patients whose clinical conditions recovered during the ATT
[32]. In contrast,the conventional methods including single-
step PCR assay and culture for M.Tb all revealed negative
results for a series of 27 CSF specimens during the clinical
treatment course of 7 patients [32]. The nested PCR assay
is a useful assay technique with superior sensitivity and
speciﬁcity. Because of the demonstration of the capacity of
the nested PCR assay in the diagnosis of diﬃcult cases in
whichotherconventionalassaymethodscannotdetectM.Tb,
theauthorsspeculatedthat,ifthisassaytechniquewaswidely
and appropriately used within clinical practice, it would be a
powerful tool for the rapid and accurate diagnosis of CNS
tuberculosis.
Currently, although the wide use of nested PCR assay in
clinical practice is expected, regrettably, it has rarely been
performed for TBM diagnosis [3, 4, 17, 19, 24–27, 32]. The
main argument against the use of nested PCR assay is that,
because of its complicated, laborious, and time-consuming
procedures, it is an inadequate assay technique for routine
use in clinical examination [3, 4, 17, 19, 24–27, 32]. In
addition, owing to its markedly increased sensitivity and the
requirement for an additional ampliﬁcation step, in general,
it is considered that cross-contamination can easily occur
through the nested PCR assay procedure [3, 4, 17, 19, 24–27,
32]. However, the possibility of cross-contamination can be
minimized by good laboratory practice. Certainly, the nested
PCR assay may be inadequate for routine use in clinical
examinations dealing with many sample specimens such as
screening examinations. However, even if any other “simple”
assay methods are used for TBM diagnosis, a negative
result cannot exclude the possibility of M.Tb infection,
and clinical judgment in TBM diagnosis remains a serious
problem with the requirement of an appropriate clinical
examination [2]. In actual clinical practice, the diagnosis of
CNS tuberculosis requires not a screening examination but
rather a deﬁnitive examination. Therefore, the nested PCR
assay should become a prominent and useful assay technique8 Tuberculosis Research and Treatment
Table 2: Sequences of primers and TaqMan probes for WR-QNRT-PCR assays.
Objective Target Type Sequence
PCR
product
size
First step
PCR
Wild M.Tb DNA (MPT64)
or W-plasmid
WFl: Outer wild forward
primer
WRl: Outer wild reverse
primer
5 -ATCCGCTGCCAGTCGTCTTCC-3 
Total 21 nucleotides, A:2, T:6, G:4, C:9 (GC% 62)
5 -CTCGCGAGTCT AGGCCAGCAT-3 
Total 21 nucleotides, A:4, T:4, G:6, C:7 (GC% 62)
239 bp
New internal control
(NM-plasmid)
MFl: Outer mutation forward
primer
MRl: Outer mutation reverse
primer
5 -TCGATTCTGTCCCACCGCCGT-3 
Total 21 nucleotides, A:2, T:6, G:4, C:9 (GC% 62)
5 -AGACTCGACGCGTAGTCCTCG-3 
Total 21 nucleotides, A:4, T:4, G:6, C:7 (GC% 62)
Wild M.Tb DNA (MPT64)
or W-plasmid
TqMn-WF2: TaqMan inner
wild forward primer
TqMn-WR2: TaqMan inner
wild reverse primer
5 -GTGAACTGAGCAAGCAGACCG-3 
Total 21 nucleotides, A:7, T:2, G:7, C:5 (GC% 57)
5 -GTTCTGATAATTCACCGGGTCC-3 
Total 22 nucleotides, A:4, T:7, G:5, C:6 (GC% 50)
Second step
PCR
New internal control
(NM-plasmid)
TqMn-MF2: TaqMan inner
mutation forward primer
TqMn-MR2: TaqMan inner
mutation reverse primer
5 -AGATCGGATAGCCAGCACGGA-3 
Total 21 nucleotides, A:7, T:2, G:7, C:5 (GC% 57)
5 -TGCGCTGCGTCGACATATTCT A-3 
Total 22 nucleotides, A:4, T:7, G:5, C:6 (GC% 50)
77 bp
Wild M. Tb DNA (MPT64)
or W-plasmid
TqMn-W-VIC: TaqMan
probe- wild-VIC
5 -VIC-TATCGAT
AGCGCCGAATGCCGG-TAMRA-3 
Total 22 nucleotides, A:5, T:4, G:7, C:6 (GC% 59)
New internal Control
(NM-plasmid)
TqMn-M-FAM: TaqMan
probe-mutation-FAM
5 -FAM-ATGGGACGGCTAGCAATCCGTC-
TAMRA-3 
Total 22 nucleotides, A:5, T:4, G:7, C:6 (GC% 59)
Underline: artiﬁcial sequence.
if used on well-deﬁned and appropriate clinical specimens
collected from “highly suspected” TBM patients. Finally, a
remaining challenge of using PCR-based assay methods in
the diagnosis of CNS tuberculosis is the requirement for
an appropriate laboratory infrastructure to perform these
more sophisticated assay techniques; it is a fact that the
infrastructure is often lacking in areas where TBM is highly
endemic. This is a crucial issue that should be solved as soon
as possible in the diagnosis of CNS tuberculosis.
7.Development ofNovel
DiagnosticAssayTechniqueBasedon
PCR for CNS Tuberculosis
Recently, the authors developed an internally controlled
novel “wide-range (WR)” quantitative nested real-time
(QNRT) PCR assay for M.Tb DNA, in order to rapidly diag-
nose CNS tuberculosis [32, 33, 38, 40, 41]. This technique
combinesthehighsensitivityofnestedPCRwiththeaccurate
quantiﬁcation of real-time (TaqMan) PCR (Figure 2(a))
[40].
In WR-QNRT-PCR assay, two types of original plasmid,
“wild” (W) and “new mutation” (NM) plasmids, were
prepared for quantitative detection of M.Tb DNA [40,
41]. W-plasmid, which was inserted a 239-base-pair (bp)
DNA fragment of the MPT64 gene into pCR 2.1 vector
(Invitrogen Corp., San Diego, CA, USA), was constructed
for use as standard template (Figure 2(b)) [40]. NM-plasmid
was developed on the basis of the W-plasmid for use
as a new internal control “calibrator” in WR-QNRT-PCR
assay (Figure 2(b)) [40]. In NM-plasmid, a total of ﬁve
regions, where two pairs of (outer and inner) forward and
reverse primers and TaqMan probe annealed, were replaced
with artiﬁcial random nucleotides (Figure 2(b)) [40]. The
sequences of the artiﬁcial random nucleotides were set to
have the same nucleotide composition as MPT64 of wild
M.Tb [40, 41]. For use in WR-QNRT-PCR assay, four pairs
of speciﬁc primers and two types of speciﬁc TaqMan probes
were prepared. The sequences and positions of these primers
and probes are shown in Table 2 and Figure 2(b) [40, 41].
The two pairs of forward and reverse primers (outer primer
pair WF1 and WR1 for use at the ﬁrst step and inner primer
pair TqMn-WF2 and TqMn-WR2 for use at the second step)
andTaqManprobe(TqMn-W-VIC)werespeciﬁcforMRT64
of wild M.Tb or W-plasmid. In contrast, the two pairs of
forward and reverse primers (outer primer pair MF1 and
MR1 and inner primer pair TqMn-MF2 and TqMn-MR2)
and TaqMan probe (TqMn-M-FAM) were speciﬁc for the
artiﬁcial random nucleotides in NM-plasmid for use as a
new internal control “calibrator.” These primers and probes
were set to have the same nucleotide composition but a
diﬀerent and random sequence (Table 2)[ 40, 41]. Therefore,
the annealing eﬃciencies of these primers and probes to wild
MPT64 or NM-plasmid as a template can be regarded as the
same.
WR-QNRT-PCR assay consists of two consecutive PCR
ampliﬁcation steps, which are conventional PCR at theTuberculosis Research and Treatment 9
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Figure 2: The principle of wide-range (WR) quantitative nested real-time (QNRT) PCR assay and its results. (a) A schema indicating the
principle of WR-QNRT-PCR assay. (b) A schema of wild (W) and new mutation (NM) plasmids NM-plasmid was developed for use as a
new internal control. (c) The speciﬁc standard curve to detect Mycobacterium tuberculosis (M.Tb) DNA or W-plasmid quantitatively. (d)
The speciﬁc standard curve to detect the NM-plasmid as a new internal control quantitatively. (e) Ampliﬁcation curves for 103 copies of
NM-plasmids as a new internal control. (f) One-way ANOVA against Ct values for 103 copies of NM-plasmid. (g) The progress of M.Tb
DNA copy numbers calculated by the WR-QNRT-PCR assay during clinical time course in 10 suspected tuberculous meningitis (TBM)
patients (cases 3 and 8–16). Statistical comparison between the cases in which anti-tuberculosis treatment (ATT) was eﬀective (cases 8–14
and 16) and those in which it was not eﬀective (cases 3 and 15) was carried out by repeated-measure ANOVA. (h) Cranial MRI ﬁndings for
cases 11 and 12 on admission. 1, 2: Cranial MRI ﬁndings for case 11. 1: FLAIR image (TR 9000/TE 110). High-intensity lesions of cerebral
infarction (circle), which were probably caused by tuberculous vasculitis, are noted on both sides of the frontal lobe. 2: T1-WI (TR 500/TE
17). A cranial tuberculoma was noted in the right thalamus. 3, 4, 5: Cranial MRI ﬁndings (Gd T1-WI: TR 400/TE 15) for case 12. Multiple
cranialtuberculomaswithmarkedGdenhancement(arrows)werenoted(3:midbrain,4:rightcerebellum,5:righttemporallobe).(i)Result
of simple regression analysis between M.Tb DNA copy number (y axis) and clinical stage of TBM (x axis).
ﬁrst step and real-time (TaqMan) PCR at the second step
(Figure 2(a)) [33, 38, 40, 41]. In this assay, the entire
procedure including extraction, ampliﬁcation, and detection
for both M.Tb DNA and NM-plasmid as a new internal
control is performed simultaneously under the same assay
conditions by using four pairs of primers and two probes
that have equivalent annealing eﬃciency to the respective
templates. Therefore, the initial copy number of M.Tb DNA
in CSF samples can be calculated by the ampliﬁcation
ratio against the new internal control (NM plasmid) as a
“calibrator,” using the following equation; X:W = C:M∴X
= W × C/M. (X, the initial copy number of M.Tb DNA
per 1mL of CSF sample; C, the initial copy number of
the new internal control (=“calibrator” 103 copies of NM-
plasmid); W and M, the copy numbers of M.Tb DNA and
NM-plasmid, respectively, after passing through extraction
and PCR ampliﬁcation procedures.) [40, 41]I nM.Tb,i t
is universally acceptable that a single copy of MPT64 geneTuberculosis Research and Treatment 11
represents one bacterial cell. Therefore, it can be considered
that the copy numbers calculated by WR-QNRT-PCR assay
correspond to the bacterial cell numbers of M.Tb in CSF
samples.
For WR-QNRT-PCR assay, two speciﬁc standard curves
for quantitative detection of M.Tb DNA and NM-plasmid
as a new internal control are needed [40, 41]. The precision
of the standard curve is the principal factor for quantitative
detection in real-time (TaqMan) PCR assay [40, 41]. The
two speciﬁc standard curves are shown in Figures 2(c)
and 2(d) [40, 41]. In simple regression analysis, both of
these two standard curves demonstrated a signiﬁcant linear
relationship (R2 > 0.99) between the threshold cycle (Ct)
values (y axis) and log of the starting copy numbers for
each standard template (x axis). In both standard curves,
no signiﬁcant diﬀerences were found among the plots in
repeated experiments (n = 10; F = 1.007, P = 0.65
and F = 1.015, P = 0.53) by two-way ANOVA. The
PCR-eﬃciency (Eﬀ) of real-time PCR can be calculated by
the slope of the standard curve, in the following equation:
PCR − Eﬀ = 10(−1/slope) − 1. The PCR-Eﬀ calculated by
this equation based on the slopes (−3.33 or −3.28) of two
standard curves was 99.7 or 101.8%, respectively [40, 41].
These results indicated that the eﬃciencies of ampliﬁcation
and detection for both M.Tb DNA and the new internal
control were almost equivalent in the WR-QNRT-PCR assay.
When a value of 103 copies of NM-plasmid was set
as the optimal copy number of new internal control, the
ampliﬁcation curves of NM-plasmids revealed extremely
uniform patterns in all starting copy numbers (1–105)o f
W-plasmids as a mimic of M.Tb DNA (Figure 2(e)) [40]. In
addition,theCt valuesfor103 copiesoftheNM-plasmidalso
revealed statistically signiﬁcant uniform variance between all
starting copy numbers of W-plasmids (F = 1.086, P =
0.774) by one-way ANOVA (Figure 2(f)) [40]. These results
indicated that there was no interference between M.Tb DNA
and the new internal control in the entire PCR ampliﬁcation
procedures. Therefore, NM-plasmid could be regarded as
appropriate for use as a new internal control “calibrator”
in WR-QNRT-PSR assay. Owing to the development of
NM-plasmid, the WR-QNRT-PCR assay enabled statistically
signiﬁcantstableandaccuratequantitativedetectionofM.Tb
DNA with a wide detection range (1–105 copies) [40, 41].
The authors examined the clinical usefulness of the
WR-QNRT-PCR assay for rapid and accurate diagnosis
and assessment of the clinical course of CNS tuberculosis
[41]. Twenty-four patients with clinically suspected TBM
and 29 non-TBM control patients were collected between
1998 and 2005 [41]. A total of 67 CSF samples were
collected from these 24 patients. Of 67 CSF samples, 43
were available serially from the 10 patients (cases 3 and
8–16) who had followups of more than 2 weeks [41].
Table 3 summarizes the clinical features of the 24 suspected
TBM patients upon admission (before ATT) [41]. All 24
patients met the (A) clinical criteria and (B) supporting
evidence for TBM (shown in Table 3) and were classiﬁed
as 8 “conﬁrmed” cases (cases 1 to 8) (CSF culture positive
for M.Tb) and 16 “highly probable” cases (cases 9 to 24)
(meeting all the clinical criteria and with three positive
results for supporting evidence, but having no bacterial
isolation). In clinical applications, the WR-QNRT-PCR assay
revealed suﬃciently high sensitivity (95.8%) and speciﬁcity
(100%) for 24 clinically suspected TBM patients [41]. The
measured copy numbers of M.Tb DNA (per 1mL of CSF)
are shown in Table 3 [41]. In conditional logistic regression
analysis,acopynumberofM.TbDNA(per1mLCSF)>8000
was an independent risk factor for poor prognosis of TBM
(=death) (OR = 16.142, 95%CI = 1.191–218.79,
∗P =
0.0365) [41]. In the diachronic study, the copy numbers
of M.Tb DNA demonstrated signiﬁcant alterations during
the clinical treatment course in 10 suspected TBM patients,
in these 10 patients including 2 “conﬁrmed” cases (cases
3 and 8) and 8 “highly probable” cases (cases 9–16) [41].
The classical cultures for M.Tb revealed positive results in
only three out of 43 serial CSF samples collected during
the clinical treatment course in cases 3 and 8. In contrast,
the quantitative detection of M.Tb DNA was possible in 25
CSF samples (58.1%) in the WR-QNRT-PCR assay [41].
In addition, the copy numbers of M.Tb DNA decreased
gradually to below the detection limit of the WR-QNRT-
PCR assay in the 8 patients (cases 8–14 and 16) for whom
ATT was eﬀective and who demonstrated improvement in
both clinical stages and routine CSF ﬁndings during clinical
treatment course (Figure 2(g)) [41]. However, in cases 3 and
15, in whom ATT was not eﬀective and who died due to
aggravationofTBM,thecopynumberswerecontinuallyhigh
throughout the clinical course (Figure 2(g)) [41]. The trend
in the alterations of M.Tb DNA copy numbers during clin-
ical treatment course demonstrated a signiﬁcant diﬀerence
(
∗P = 0.0041) between the ATT eﬀective cases (cases 8–
14 and 16) and the ATT noneﬀective cases (cases 3 and
8) by repeated-measure ANOVA (Figure 2(g)) [41]. In cases
11 and 12, initial cranial MRI on admission demonstrated
multiple intracranial focal masses that were regarded as
typical tuberculomas (Table 4 and Figure 2(h)) [38, 41].
In these two cases with tuberculomas, after conversion to
negative results of WR-QNRT-PCR assay, transient positivity
wasonceagainrevealedwithoutanysymptomsofmeningitis
during the course of ATT [38, 41]. In general, tuberculomas
often occur along with TBM, but certainly may occur in
the absence of TBM [2]. Tuberculomas in these two cases
disappeared at 5 and 3 months after the initiation of ATT
during the follow-up MRI (Table 4)[ 38, 41]. Interestingly,
WR-QNRT-PCR assay results became completely negative
along with the disappearance of tuberculomas [38, 41]. The
authors speculate that the transient detections of M.Tb DNA
by WR-QNRT-PCR assays in these two cases during the ATT
were correlated with tuberculomas. A small amount of M.Tb
might have survived within the tuberculomas. The high
sensitivity of WR-QNRT-PCR assay might have detected a
little DNA of extinct M.Tb leaking into CSF along with
the rupture of tuberculomas by ATT. These ﬁndings suggest
that the combination of molecular-based techniques and
neuroradiographic techniques is a promising and powerful
diagnostic tool for TBM and tuberculomas in actual clinical
practice. To our knowledge, there have been no previous
reports on cases such as these two cases; therefore, they
may be regarded as clinically important. Moreover, in simple12 Tuberculosis Research and Treatment
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i
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n
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i
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p
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c
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ﬀ
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c
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c
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c
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p
r
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c
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i
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e
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u
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b
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c
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c
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c
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b
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c
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b
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c
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ﬁ
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c
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c
h
a
s
C
S
F
c
u
l
t
u
r
e
p
o
s
i
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p
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c
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c
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c
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i
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c
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c
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c
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c
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b
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c
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b
e
r
c
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c
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c
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c
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c
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c
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p
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b
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c
u
l
o
s
i
s
t
r
e
a
t
m
e
n
t
.14 Tuberculosis Research and Treatment
T
a
b
l
e
4
:
T
h
e
d
e
t
a
i
l
o
f
c
l
i
n
i
c
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i
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b
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c
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−
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−
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c
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b
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c
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i
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c
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c
e
r
e
b
r
o
v
a
s
c
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c
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p
i
c
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p
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regression analysis, signiﬁcant correlation (R2 = 0.597,
∗P < 0.0001) was demonstrated between M.Tb DNA copy
number and clinical stage of TBM (Figure 2(i)) [41]. These
diachronic study results indicate that quantitative analysis
by WR-QNRT-PCR assay is very useful for assessing the
clinical course of TBM and ATT response [41]. To our
knowledge, there have been no previous studies that serially
assessed the quantity of DNA or bacterial cell numbers of
M.Tb in CSF samples throughout the clinical course of CNS
tuberculosis [41]. In actual clinical application, the WR-
QNRT-PCR assay demonstrated signiﬁcant accuracy and
reliability for quantitative detection of M.Tb DNA in CSF
samples owing to the development of NM-plasmid used as
a new internal control. Therefore, this novel assay technique
could be regarded as a useful and advanced method for
rapidly and accurately diagnosing CNS tuberculosis [40, 41].
However, this novel assay technique is not widely used
in routine clinical examination. It may be that the two
consecutive ampliﬁcation steps of WR-QNRT-PCR assay
are regarded as a complicated and laborious procedure.
Therefore, the authors are developing a further novel and
“simpler and low-cost” assay technique with quantiﬁcation
and high-sensitivity almost equivalent to those with the WR-
QNRT-PCR assay by one step of standard real-time PCR
assay. This developing assay technique is a combination
of the whole genome ampliﬁcation (WGA) method with
the real-time (TaqMan) PCR assay technique. The whole
genome ampliﬁcation (WGA) method provides a possibility
of amplifying a small amount of high-quality DNA and there
are several such techniques using commercially available kits
at a reasonable price [50–52]. In particular, in these kits for
the WGA method, a kit based on the multiple displacement
ampliﬁcation (MDA) technique has been found in many
studies to provide the most balanced genome ampliﬁcation
[50–52]. The MDA technique is a superior method in
which genomic DNA is continuously ampliﬁed by using
Phi29 DNA polymerase of bacteriophage origin and random
hexamer primers [50–52]. In this case, the authors used the
GenomiPhi V2 kit (GE Healthcare Life Sciences, Uppsala,
Sweden) based on the MDA technique. Because a small
amount of M.Tb DNA extracted and puriﬁed from a CSF
specimen for use as a template can be ampliﬁed directly
using the GenomiPhi V2 kit, the ﬁrst-step PCR in the
WR-QNRT-PCR assay can be omitted. This assay technique
that is currently being developed can markedly simplify the
procedure of WR-QNRT-PCR assay by innovation of the
WGA method. Therefore, although it is yet to be reported, its
wider use as a beneﬁcial approach for clinical examination is
expected in actual clinical practice.
As described above, CNS tuberculosis including TBM
is the severest form of M.Tb infection, causing death and
serious sequelae [1–5]. In addition, owing to an increas-
ing number of immunocompromised hosts caused by the
prevalence of AIDS, increasing numbers of older people,
and the wider use of immunosuppressive agents such as
corticosteroid, CNS tuberculosis remains a serious clinical
and social problem [1–5, 43–46]. In particular, in the
underdevelopedanddevelopingcountriesinAsiaandAfrica,
in which there are many exacerbating social problems such
as poverty, overcrowding, and malnutrition, and so forth,
the epidemic of M.Tb infection including TBM is regarded
as a serious social and demographic crisis [1, 2, 43–46]. The
authors consider that the novel assay techniques that we have
developed are needed and should be used in these places.
The wider use of our novel assay techniques will lead to an
increase of the number of deﬁnitively diagnosed cases within
the early stage of TBM and the improvement of treatment
results for TBM; therefore, they should make a signiﬁcant
medical and social contribution in these countries. It is
hoped that our eﬀorts to develop novel and more rapid,
accurate, highly sensitive, quantitative, simple, and low-cost
assay techniques for the diagnosis of CNS tuberculosis will
helptoimprovethelevelofmedicalcareglobally,particularly
in underdeveloped or developing countries.
8. Conclusion
Recently, instead of the conventional “gold standard” based
on bacteriological techniques, various approaches have been
attempted for rapid and accurate diagnosis of CNS tuber-
culosis with high sensitivity. In this paper, an overview of
recent progress of the NAA methods, mainly highlighting
the PCR assay technique, was presented. In particular, the
innovation of nested PCR assay technique is worthy of note
given its contribution to improve the diagnosis of CNS
tuberculosis. Although a novel assay technique, which is
internally controlled and combines the high sensitivity of
nested PCR with the accurate quantiﬁcation of real-time
(TaqMan)PCR,namely,“WR-QNRT-PCRassay,”isreported
as a rapid diagnostic method in TBM, it is not widely used
in routine clinical examination. This novel assay technique
with high sensitivity in addition to accurate quantiﬁcation is
useful for not only the rapid diagnosis of CNS tuberculosis
but also the prediction of prognosis and assessing the eﬀect
of ATT during the clinical course of TBM. Therefore, in
actual clinical practice, its wider use for the diagnosis of CNS
tuberculosis is expected in the future.
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